CRISPR therapy moves into routine European clinical care

Charité reported Germany’s first beta-thalassemia patient treated with exa-cel, with the 19-year-old transfusion-free four months after treatment. The case is a concrete validation of commercial gene-editing therapy, while durability, conditioning toxicity, manufacturing scale, reimbursement, and long-term safety remain unresolved.